Observational Study of the Use of 8% Capsaicin Patch in Children 0 to 18 Years Old
NCT ID: NCT05299294
Last Updated: 2024-09-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
160 participants
OBSERVATIONAL
2022-05-12
2027-09-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Medical data will be recorded and at home, the child or his family will collect pain assessment data.
Tolerance will be monitored at home by phone call from investigational team every 24 hours until normalization. (Less than 24 hours for 75%, 100% to 72 hours on unpublished personal series.) Children will be assessed via scales at inclusion and 1-month, 3-month and 6-month.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Analgesic Effectiveness of Capsaicin 8% Cutaneous Patch in Children
NCT05997979
Development of an Online Program to Help Manage Chronic Pain in Children and Teenagers
NCT03992976
Treatment Options for Pediatric Chronic Pain: How do we Best Disseminate Our Scientific Findings
NCT05239299
Offset Analgesia as a Measure of Central Sensitization in Children
NCT03445403
Abdominal Pain Disorders Functional in Children: Impact of Hypno-analgesia on the Autonomic Balance
NCT02830698
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Treatment application will follow recommendations and be realized in out patient clinic with trained nurses.
Tolerance will be assessed by phone call every 24 Hours by investigational team until normalization. Expected duration is less than 24 Hours for 75% patients and 100 % at 72 Hours, from unpublished personal data.
Efficacy will be monitored with usual pain and neuropathic pain tools, adapted to age and cognitive capacities, one month after application.
Treatment may be done three times if needed with a three month interval between each capsaicin patch application.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Data collection
Collecting data on children receiving capsaicine 8% patch for localized neuropathic pain
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* capsaicin 8% patch treatment indication validated in a pediatric chronic pain center
* agreement for participation by child and parents
Exclusion Criteria
* already treated in the same study in an other investigation center
* non willing to participate or parents not willing participation to the study
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondation de France
OTHER
Fondation Apicil
OTHER
University Hospital, Brest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Philippe J Le Moine, MD
Role: PRINCIPAL_INVESTIGATOR
CHRU of Brest
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Angers
Angers, France, France
CHU Bordeaux
Bordeaux, France, France
CHR Bourg en Bresse
Bourg-en-Bresse, France, France
CHU de Brest
Brest, France, France
CHU Caen
Caen, France, France
CHU Grenoble
Grenoble, France, France
CHU Lille
Lille, France, France
CHU Limoges
Limoges, France, France
CHU Marseille
Marseille, France, France
CHU Montpellier
Montpellier, France, France
CHU Nancy
Nancy, France, France
CHU Nantes
Nantes, France, France
CHU Robert Debré
Paris, France, France
CHU Trousseau
Paris, France, France
CHU Rouen
Rouen, France, France
CHRU Strasbourg
Strasbourg, France, France
CHU Toulouse
Toulouse, France, France
Institut Gustave Roussy
Villejuif, France, France
CHU d'Amiens
Amiens, , France
CHU Lyon
Lyon, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
29BRC21.0184 (CAPSULE)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.